Inhibition of β2-Microglobulin/Hemochromatosis Enhances Radiation Sensitivity by Induction of Iron Overload in Prostate Cancer Cells

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Josson, Sajni ^a   Matsuoka, Yasuhiro ^a   Gururajan, Murali ^a   Nomura, Takeo ^b   Huang, Wen Chin ^a   Yang, Xiaojian ^a   Lin, Jin tai ^a   Bridgman, Roger ^c   Chu, Chia Yi ^a   Johnstone, Peter A ^d   Zayzafoon, Majd ^e   Hu, Peizhen ^a   Zhau, Haiyen ^a   Berel, Dror ^a   Rogatko, Andre ^a   Chung, Leland W K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AUBURN UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; DNA; HEAT SHOCK PROTEIN; IRON; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA REPAIR; GENE DELETION; HEMOCHROMATOSIS; HUMAN; IMMUNOCOMPETENT CELL; IRON OVERLOAD; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTIBODIES; BETA 2-MICROGLOBULIN; COMBINED MODALITY THERAPY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; IRON OVERLOAD; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; MULTIPROTEIN COMPLEXES; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880026400     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068366     Document Type: Article

References (31)

1. Zhau HE, Li CL, Chung LW, (2000) Establishment of human prostate carcinoma skeletal metastasis models. Cancer 88: 2995-3001.
2. Huang WC, Wu D, Xie Z, Zhau HE, Nomura T, et al. (2006) beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res 66: 9108-9116.
3. Yang J, Qian J, Wezeman M, Wang S, Lin P, et al. (2006) Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 10: 295-307.
4. Josson S, Nomura T, Lin JT, Huang WC, Wu D, et al. (2011) beta2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 71: 2600-2610.
5. Yang J, Zhang X, Wang J, Qian J, Zhang L, et al. (2007) Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 110: 3028-3035.
6. Nomura T, Huang WC, Seo S, Zhau HE, Mimata H, et al. (2007) Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol 178: 292-300.
7. Huang WC, Zhau HE, Chung LW, (2010) Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. J Biol Chem 285: 7947-7956.
8. Feder JN, Tsuchihashi Z, Irrinki A, Lee VK, Mapa FA, et al. (1997) The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 272: 14025-14028.
9. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, et al. (1998) The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A 95: 1472-1477.
10. Rothenberg BE, Voland JR, (1996) beta2 knockout mice develop parenchymal iron overload: A putative role for class I genes of the major histocompatibility complex in iron metabolism. Proc Natl Acad Sci U S A 93: 1529-1534.
11. Muckenthaler MU, Rodrigues P, Macedo MG, Minana B, Brennan K, et al. (2004) Molecular analysis of iron overload in beta2-microglobulin-deficient mice. Blood Cells Mol Dis 33: 125-131.
12. Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, et al. (2006) RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 25: 1554-1559.
13. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, et al. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577-2581.
14. Josson S, Sung SY, Lao K, Chung LW, Johnstone PA, (2008) Radiation modulation of microRNA in prostate cancer cell lines. Prostate 68: 1599-1606.
15. Yang X, Shi C, Tong R, Qian W, Zhau HE, et al. (2010) Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res 16: 2833-2844.
16. Gururajan M, Simmons A, Dasu T, Spear BT, Calulot C, et al. (2008) Early growth response genes regulate B cell development, proliferation, and immune response. J Immunol 181: 4590-4602.
17. Shiota M, Bishop JL, Nip K, Zardan A, Takeushi A, et al. (2013) Hsp27 regulates epithelial mesenchymal transition, metastasis and circulating tumor cells in prostate cancer. Cancer Res.
18. Teng Y, Ngoka L, Mei Y, Lesoon L, Cowell JK, (2012) HSP90 and HSP70 proteins are essential for stabilization and activation of WASF3 metastasis-promoting protein. J Biol Chem 287: 10051-10059.
19. Adhikari S, Choudhury S, Mitra PS, Dubash JJ, Sajankila SP, et al. (2008) Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem 8: 351-357.
20. Garre P, Briceno V, Xicola RM, Doyle BJ, de la Hoya M, et al. (2011) Analysis of the oxidative damage repair genes NUDT1, OGG1, and MUTYH in patients from mismatch repair proficient HNPCC families (MSS-HNPCC). Clin Cancer Res 17: 1701-1712.
21. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM, (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57: 3325-3330.
22. Gross M, Top I, Laux I, Katz J, Curran J, et al. (2007) Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clin Cancer Res 13: 1979-1986.
23. Teasdale C, Mander AM, Fifield R, Keyser JW, Newcombe RG, et al. (1977) Serum beta2-microglobulin in controls and cancer patients. Clin Chim Acta 78: 135-143.
24. Hemmingsen L, Skaarup P, (1977) Urinary excretion of ten plasma proteins in patients with renal carcinoma. Scand J Urol Nephrol 11: 41-46.
25. Shuster J, Gold P, Poulik MD, (1976) beta 2-microglogulin levels in cancerous and other disease states. Clin Chim Acta 67: 307-313.
26. Ward DG, Nyangoma S, Joy H, Hamilton E, Wei W, et al. (2008) Proteomic profiling of urine for the detection of colon cancer. Proteome Sci 6: 19.
27. Huang WC, Havel JJ, Zhau HE, Qian WP, Lue HW, et al. (2008) Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clin Cancer Res 14: 5341-5347.
28. Huang WC, Xie Z, Konaka H, Sodek J, Zhau HE, et al. (2005) Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res 65: 2303-2313.
29. Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK, et al. (2007) cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 26: 5070-5077.
30. Stevens RG (2000) Hemochromatosis heterozygotes may constitute a radiation-sensitive subpopulation. Radiat Res 154: 725-726;discussion 726-727.
31. Kuvibidila S, Gauthier T, Warrier RP, Rayford W, (2004) Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate cancer and the implications for body-iron stores. J Lab Clin Med 144: 176-182.